• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did Open Source AI Benchmark Just Shift Doximity (DOCS) Stock Narrative?

    Simply Wall St·10/04/2026 15:14:41
    語音播報
    • Doximity recently released Bedside Bench, an open-source benchmark that uses realistic clinical scenarios to assess AI performance on drug safety, evidence use and health equity, where its Doximity Ask system ranked first in independent testing.
    • The focus on open-source, clinician-shaped evaluations positions Doximity as not just a tool provider but also a standard-setter for how clinical AI is measured and trusted at the bedside.
    • We will now look at how Doximity’s role in defining clinical AI benchmarks could reshape the investment narrative around its AI monetisation.

    Scan how Doximity’s Bedside Bench approach fits into a wider shift toward clinically focused AI, then size up a curated set of 35 healthcare AI stocks that could be shaping the same trend.

    Doximity Investment Narrative Recap

    Doximity appeals most if you think its physician network and clinical tools can keep deepening usage while AI products, including Ask and Scribe, eventually translate that engagement into steadier revenue from pharma and health systems. The Bedside Bench news mainly reinforces the clinical credibility side of that belief rather than changing near term numbers.

    The key near term swing factor still looks like AI monetisation catching up with higher spend as management leans into compute, R&D and marketing through fiscal 2027. The biggest risk remains that pharma budgets stay tight and AI contracts ramp slower than costs, which could keep growth and margins closer to recent levels.

    The Bedside Bench launch ties directly into an existing operational catalyst. Independent testing already showed Doximity Ask ahead of other US based models in the NOHARM study from Stanford and Harvard, and Fireworks’ new Index now echoes that with top ranking results on clinical scenarios that matter for safety, evidence use and equity.

    For you as a shareholder candidate, that kind of third party grading can matter if it supports AI led conversations with pharma and health system buyers who want measurable safety and accuracy. The commercial question still centers on how quickly those credibility signals convert into larger, multi budget contracts for Ask, Scribe, AI Search and broader enterprise AI deals.

    Doximity’s AI Benchmarks Against Analyst Expectations

    Doximity's narrative projects US$795.0 million revenue and US$198.5 million earnings by 2029. This assumes 6.6% yearly revenue growth and an earnings increase of about US$31.5 million from US$167.0 million today.

    Uncover how Doximity's fair value indicates a 6% potential upside to its current price, which could narrow quickly if sentiment improves.

    NYSE:DOCS 1-Year Stock Price Chart
    NYSE:DOCS 1-Year Stock Price Chart

    Exploring Other Perspectives

    One bullish catalyst that contrasts with the cautious baseline is how far some analysts already stretch their earnings hopes. Before the Bedside Bench news, the most optimistic forecasts had Doximity reaching about US$848.5 million revenue and US$256.6 million earnings by 2029. That is far above the consensus, which shows how widely opinions differ and why this new AI benchmark could eventually shift a few narratives on your screen.

    Explore 4 other Doximity fair value estimates, including one that suggests up to 24% potential upside from the current price.

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Ideas Beyond Doximity?

    If you want to put Doximity in context, it can help to line it up next to a few very different types of opportunities. Use the Simply Wall St Screener to compare the business against other stocks that match the way you prefer to invest.

    • For investors who want income resilience alongside potential price gains, scan a curated set of steady payers with 7 dividend fortresses that already clear some basic quality checks.
    • If protecting capital is the first priority, focus on resilience by reviewing a 31 resilient stocks with low risk scores that filters for companies with stronger risk profiles.
    • Hungry for something off the beaten path, but still grounded in fundamentals, sort through a 19 high quality undiscovered gems that rarely appear on mainstream radars.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.